Clinical Trial Logistics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Clinical Trial Logistics Market Report is Segmented by Type of Service (Transportation, and More), by Clinical Phase (Phase I, and More), by Therapeutic Area (Cardiovascular Diseases and More), by End-User (Bio-Pharma Manufacturers and More), by Temperature Range (Cold Chain and Non Cold Chain), and by Geography (North America, and More). The Report Offers Market Size and Forecast Values (USD) for all the Above Segments.

Clinical Trial Logistics Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Clinical Trial Logistics Market with other markets in Logistics Industry

Clinical Trial Logistics Market Analysis by Mordor Intelligence

The Clinical Trial Logistics Market size is estimated at USD 5.80 billion in 2025, and is expected to reach USD 9.04 billion by 2030, at a CAGR of 9.27% during the forecast period (2025-2030).

Robust growth stems from decentralized trial adoption, rising ultra-cold chain shipments for cell and gene therapies, and global regulatory harmonization encourages multi-regional studies. Direct-to-patient delivery networks are reshaping distribution models and boosting value-added services, while predictive analytics limit wastage caused by volatile patient recruitment. Capital-intensive investments in temperature-controlled hubs and IoT tracking strengthen service reliability, and outsourcing momentum among biopharma sponsors fuels demand for integrated, end-to-end solutions.

Key Report Takeaways

  • By service, transportation held 68.2% of the clinical trial logistics market share in 2024. The clinical trial logistics market for value-added services is set to expand at a 10.72% CAGR between 2025-2030.
  • By clinical phase, Phase III accounted for 45.67% of the clinical trial logistics market revenue share in 2024. The clinical trial logistics market for Phase I is projected to grow at 10.49% CAGR between 2025-2030.
  • By therapeutic area, oncology led with 36.19% of the clinical trial logistics market size in 2024. The clinical trial logistics market for rare and orphan diseases will rise to 12.13% CAGR between 2025-2030.
  • By end-user, bio-pharma manufacturers represented 55.35% of the clinical trial logistics market share in 202. The clinical trial logistics market for the CRO/CMO segment records the fastest 11.32% CAGR between 2025-2030.
  • By temperature range, cold-chain services commanded 65.57% of the clinical trial logistics market size in 2024. The clinical trial logistics market for cold chain is advancing at an 11.85% CAGR between 2025-2030.
  • By geography, North America led with 38.83% revenue share in 2024, while Asia-Pacific is projected to grow at an 11.05% CAGR through 2030.

Segment Analysis

By Service: Transportation Dominance Drives Infrastructure Investment

Transportation services generated 68.2% of 2024 revenue, underscoring the criticality of time-definite delivery within the clinical trial logistics market. DHL’s EUR 2 billion allocation for new GDP-certified hubs and expanded cold chain lanes typifies the high capital barriers DHL faces. Value-added offerings enjoy a 10.72% CAGR as sponsors bundle kitting, relabeling, and Qualified Person release to a single provider. Within transportation, road services dominate regional moves, whereas premium-priced airfreight protects time- and temperature-sensitive payloads. Integration across modes supports seamless chain-of-custody, central to sponsor audits and ICH GCP R3 compliance. 

Ongoing modal diversification strengthens resilience: chartered freighters for bulk vaccine moves, dedicated courier networks for cryogenic packages, and in-country bike couriers for same-day patient replenishment. Providers with multi-modal orchestration platforms retain an edge as the clinical trial logistics market transitions toward data-driven routing and predictive ETAs.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Clinical Phase: Early-Stage Acceleration Reshapes Resource Allocation

Phase III studies continue to absorb the largest budget share, reflecting their expansive cohorts and rigorous endpoint monitoring. Yet a 10.49% CAGR in Phase I activity signals heightened early-stage screening, particularly in precision oncology. Japan’s fast-track waiver of domestic Phase I for imported assets expedites first-in-human starts, redistributing logistics spend upstream. Adaptive protocols compress timelines, demanding nimble supply chains that can upscale from micro-dosing to multi-arm expansion without service disruption. 

Inventory digital twins enable real-time demand recalculation as dose-escalation cohorts progress, trimming waste. Sponsors increasingly stipulate service-level agreements that tie provider fees to enrolment adherence, incentivizing analytics investment. The clinical trial logistics market size for Phase I consignments is forecast to climb steadily as cell-therapy dose-finding studies proliferate.

By Therapeutic Area: Precision Medicine Drives Specialized Requirements

Oncology’s 36.19% share mirrors its pipeline dominance and the complexity of biomarker-guided regimens. Rare-disease programs, up 12.13% CAGR, demand bespoke pickups from geographically dispersed centers of excellence and bespoke kitting for minute cohorts. Logistics partners must handle companion-diagnostic kits alongside investigational products under unified tracking. 

Combination therapy trials escalate packaging variety and require harmonized shelf-life management. IoT-enabled shippers paired with blockchain audit trails protect chain-of-identity for autologous products, supporting regulator scrutiny. The clinical trial logistics market share for rare-disease consignments remains small but commands premium pricing due to service intricacy.

By End-User: Outsourcing Momentum Accelerates Service Demand

Bio-pharma sponsors produced 55.35% of 2024 revenue, yet CRO/CMO demand is accelerating at 11.32% CAGR as outsourcing deepens. Audax Private Equity’s purchase of Avantor Clinical Services indicates private-capital confidence in scalable third-party models. Sponsors offload regulatory complexity and temperature-controlled capex, while CROs seek differentiated, tech-enabled partners. 

Site networks consolidate procurement, giving logistics firms opportunities to negotiate umbrella contracts that standardize processes across hundreds of hospitals. End-to-end control of planning, distribution, reverse logistics, and data capture is becoming table stakes in the clinical trial logistics industry.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Temperature Range: Cold Chain Innovation Drives Premium Growth

Cold-chain consignments commanded 65.57% of 2024 revenue, and ultra-cold segments record the fastest 11.85% CAGR. Controlant’s Saga Card, which transmits real-time temperature and geolocation data, exemplifies innovation that expands visibility[2]Controlant, “Saga Card Real-Time Visibility Solution,” controlant.com. Providers face shortages of qualified phase-change materials, prompting vertical integration into packaging manufacture. 

Regulators increasingly inspect excursion records, raising quality-management requirements. The clinical trial logistics market size for ultra-cold moves is poised to grow by 2030, underpinning premium-margin growth as cell-therapy volumes scale.

Geography Analysis

North America claimed 38.83% of 2024 revenue, buoyed by dense sponsor headquarters, established depot networks, and mature regulatory frameworks. The region continues to invest in decentralized models and advanced analytics, although labor shortages elevate operating costs. Asia-Pacific leads expansion at an 11.05% CAGR as China surpasses the United States in new-trial count. Regulatory streamlining—such as China’s proposed 30-day IND review window—draws multinationals seeking accelerated recruitment.

Japan’s drug-lag reforms and Australia’s HREC fast-track pathways further boost regional demand. India’s CDSCO digital portal eases import permitting, spurring depot investments. The clinical trial logistics market size for APAC cold-chain consignments is projected to double between 2025 and 2030. 

Europe benefits from EMA oversight and ICH GCP R3 alignment, supporting cross-border consolidation of Phase I units and pan-EU adaptive trials. South America’s share remains modest but DHL’s Brazil-to-USA medical express lane shortens lead times to 24 hours, elevating the continent’s attractiveness for vaccine studies[3]DHL Express, “DHL Expands Next-Day Medical Express Service and Clinical Trial Platform ,” dhl.com. The Middle East and Africa see nascent growth tied to oncology trials in Gulf Cooperation Council states, although customs and power-supply reliability still impede large-scale cold-chain adoption.

Clinical Trial Logistics Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segments share of all individual segments available upon report purchase

Competitive Landscape

Competitive intensity is moderate, with global integrators (DHL, UPS, FedEx) leveraging broad networks and specialized providers (World Courier, Marken) offering niche regulatory expertise. UPS’s acquisition of Frigo-Trans and BPL strengthens European cryogenic capacity. Investment priorities include IoT sensor fleets, blockchain traceability, and machine-learning demand forecasting. 

White-space opportunities lie in ultra-cold infrastructure for autologous cell therapies, integrated direct-to-patient orchestration, and cloud platforms that marry RTSM with transport management. Start-ups delivering robotic micro-fulfilment or drone delivery pilot projects face scale-up hurdles, yet their technologies are ripe for partnership or acquisition. 

Customer stickiness hinges on audit performance, on-time metrics, and digital transparency. Providers that can guarantee continuous temperature integrity from manufacturer to patient, supported by automated compliance documentation, command pricing premiums within the clinical trial logistics market.

Clinical Trial Logistics Industry Leaders

  1. Alamc Group

  2. Parexel International Corporation

  3. DHL

  4. Marken (UPS Healthcare)

  5. Thermo Fisher Scientific – Fisher Clinical Services

  6. *Disclaimer: Major Players sorted in no particular order
Clinical Trial Logistics Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2025: DHL Group committed EUR 2 billion (USD 2.29 billion) by 2030 to expand GDP-certified Pharma Hubs and cold-chain lanes worldwide.
  • May 2025: Bionical Emas and Pharma Resources formed an exclusive global supply partnership covering multi-therapeutic trials.
  • May 2025: Perceptive eClinical introduced ClinPhone Pro, a next-gen RTSM platform with rolling forecast algorithms.
  • April 2025: DHL Express launched a next-day Brazil-to-USA medical express service for time-critical trial materials.

Table of Contents for Clinical Trial Logistics Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Ageing Population Elevates Multi-Dose Trial Demand
    • 4.2.2 Decentralised/Direct-to-Patient (DtP) Trial Adoption Accelerating Service Outsourcing
    • 4.2.3 Cell & Gene Therapy Pipeline Requiring Ultra-Cold-Chain Capabilities
    • 4.2.4 ICH GCP R3 Harmonisation Enabling Multi-Regional Trials
    • 4.2.5 Rise of Adaptive & Platform Trials Increasing Mid-Study Change Orders
    • 4.2.6 Patient-Centric Retention Strategies Driving Home-Healthcare Logistics
  • 4.3 Market Restraints
    • 4.3.1 Volatile Patient Recruitment Forecasts Causing Supply Overages & Waste
    • 4.3.2 Cross-Border Customs Delays for Biological Specimens
    • 4.3.3 Shortage of Qualified Temperature-Controlled Packaging Materials
    • 4.3.4 High Liability Insurance Costs for DtP Deliveries
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Technological Innovations in the Industry
  • 4.6 Government Regulations and Policies
  • 4.7 Porter's Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Buyers/Consumers
    • 4.7.3 Bargaining Power of Suppliers
    • 4.7.4 Threat of Substitute Products
    • 4.7.5 Intensity of Competitive Rivalry
  • 4.8 Impact of Geopolitical Events on the Market

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Service
    • 5.1.1 Transportation
    • 5.1.1.1 Road
    • 5.1.1.2 Air
    • 5.1.1.3 Others
    • 5.1.2 Warehousing & Distribution
    • 5.1.3 Value-Added Services (Labelling, Kitting, QP Release)
  • 5.2 By Clinical Phase
    • 5.2.1 Phase I
    • 5.2.2 Phase II
    • 5.2.3 Phase III
    • 5.2.4 Phase IV / Post-Marketing
  • 5.3 By Therapeutic Area
    • 5.3.1 Oncology
    • 5.3.2 Cardiovascular Diseases
    • 5.3.3 Rare / Orphan Diseases
    • 5.3.4 Immunology & Inflammation
    • 5.3.5 Endocrine & Metabolic Disorders
    • 5.3.6 Neurology & Psychiatry
    • 5.3.7 Others
  • 5.4 By End-user
    • 5.4.1 Bio-Pharma Manufacturers
    • 5.4.2 CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
    • 5.4.3 Hospitals & Clinical-Trial Sites
    • 5.4.4 Other End Users
  • 5.5 By Temperature Range
    • 5.5.1 Cold Chain
    • 5.5.1.1 Ambient (15-25 °C)
    • 5.5.1.2 Refrigerated (2–8 °C)
    • 5.5.1.3 Frozen (0 °C to -20 °C)
    • 5.5.1.4 Ultra-Cold / Cryogenic (-20 °C to -150 °C)
    • 5.5.2 Non Cold Chain
  • 5.6 By Geography
    • 5.6.1 North America
    • 5.6.1.1 Canada
    • 5.6.1.2 United States
    • 5.6.1.3 Mexico
    • 5.6.2 South America
    • 5.6.2.1 Brazil
    • 5.6.2.2 Peru
    • 5.6.2.3 Chile
    • 5.6.2.4 Argentina
    • 5.6.2.5 Rest of South America
    • 5.6.3 Asia-Pacific
    • 5.6.3.1 India
    • 5.6.3.2 China
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
    • 5.6.3.7 Rest of Asia-Pacific
    • 5.6.4 Europe
    • 5.6.4.1 United Kingdom
    • 5.6.4.2 Germany
    • 5.6.4.3 France
    • 5.6.4.4 Spain
    • 5.6.4.5 Italy
    • 5.6.4.6 BENELUX (Belgium, Netherlands, and Luxembourg)
    • 5.6.4.7 NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
    • 5.6.4.8 Rest of Europe
    • 5.6.5 Middle East And Africa
    • 5.6.5.1 United Arab of Emirates
    • 5.6.5.2 Saudi Arabia
    • 5.6.5.3 South Africa
    • 5.6.5.4 Nigeria
    • 5.6.5.5 Rest of Middle East And Africa

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Strategic Moves (M&A, Site Expansions, Partnerships)
  • 6.3 Market Share Analysis
  • 6.4 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.4.1 Almac Group
    • 6.4.2 Thermo Fisher Scientific - Fisher Clinical Services
    • 6.4.3 Marken (UPS Healthcare)
    • 6.4.4 DHL Supply Chain & Healthcare
    • 6.4.5 Parexel International Corporation
    • 6.4.6 Catalent Inc.
    • 6.4.7 PCI Pharma Services
    • 6.4.8 World Courier (Cencora)
    • 6.4.9 FedEx Clinical Transport Solutions
    • 6.4.10 Kuehne + Nagel PharmaChain
    • 6.4.11 Biocair
    • 6.4.12 Movianto (Walden Group)
    • 6.4.13 Sharp Clinical Services
    • 6.4.14 UDG Healthcare plc (Ashfield Clinical)
    • 6.4.15 Capsugel (Lonza)
    • 6.4.16 Klifo A/S
    • 6.4.17 Bilcare Limited
    • 6.4.18 Eurofins Scientific
    • 6.4.19 PRA Health Sciences (ICON plc)
    • 6.4.20 WuXi Clinical Supply Services
    • 6.4.21 Arvato Supply Chain Solutions
    • 6.4.22 DPDgroup Healthcare
    • 6.4.23 Yusen Logistics Pharma
    • 6.4.24 BioStorage Technologies*

7. Market Opportunities & Future Outlook

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Clinical Trial Logistics Market Report Scope

Clinical trial logistics is a service responsible for providing the necessary logistics for conducting clinical studies on medical devices or drugs in accordance with established protocols and relevant regulatory standards. The Clinical Trial Logistics Market is segmented by Type of Services (Delivery of Medication, Pickup of Specimens and Drug/Ancillary Supply Returns) and by Region (North America, South America, Europe, Asia-Pacific, and Middle East & Africa). The Report Offers Market Size and Forecast Values (USD) for all the Above Segments.

By Service Transportation Road
Air
Others
Warehousing & Distribution
Value-Added Services (Labelling, Kitting, QP Release)
By Clinical Phase Phase I
Phase II
Phase III
Phase IV / Post-Marketing
By Therapeutic Area Oncology
Cardiovascular Diseases
Rare / Orphan Diseases
Immunology & Inflammation
Endocrine & Metabolic Disorders
Neurology & Psychiatry
Others
By End-user Bio-Pharma Manufacturers
CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
Hospitals & Clinical-Trial Sites
Other End Users
By Temperature Range Cold Chain Ambient (15-25 °C)
Refrigerated (2–8 °C)
Frozen (0 °C to -20 °C)
Ultra-Cold / Cryogenic (-20 °C to -150 °C)
Non Cold Chain
By Geography North America Canada
United States
Mexico
South America Brazil
Peru
Chile
Argentina
Rest of South America
Asia-Pacific India
China
Japan
Australia
South Korea
South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
Rest of Asia-Pacific
Europe United Kingdom
Germany
France
Spain
Italy
BENELUX (Belgium, Netherlands, and Luxembourg)
NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
Rest of Europe
Middle East And Africa United Arab of Emirates
Saudi Arabia
South Africa
Nigeria
Rest of Middle East And Africa
By Service
Transportation Road
Air
Others
Warehousing & Distribution
Value-Added Services (Labelling, Kitting, QP Release)
By Clinical Phase
Phase I
Phase II
Phase III
Phase IV / Post-Marketing
By Therapeutic Area
Oncology
Cardiovascular Diseases
Rare / Orphan Diseases
Immunology & Inflammation
Endocrine & Metabolic Disorders
Neurology & Psychiatry
Others
By End-user
Bio-Pharma Manufacturers
CROs (Contract Research Organizations) & CMOs (Contract Manufacturing Organizations)
Hospitals & Clinical-Trial Sites
Other End Users
By Temperature Range
Cold Chain Ambient (15-25 °C)
Refrigerated (2–8 °C)
Frozen (0 °C to -20 °C)
Ultra-Cold / Cryogenic (-20 °C to -150 °C)
Non Cold Chain
By Geography
North America Canada
United States
Mexico
South America Brazil
Peru
Chile
Argentina
Rest of South America
Asia-Pacific India
China
Japan
Australia
South Korea
South East Asia (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines)
Rest of Asia-Pacific
Europe United Kingdom
Germany
France
Spain
Italy
BENELUX (Belgium, Netherlands, and Luxembourg)
NORDICS (Denmark, Finland, Iceland, Norway, and Sweden)
Rest of Europe
Middle East And Africa United Arab of Emirates
Saudi Arabia
South Africa
Nigeria
Rest of Middle East And Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected size of the clinical trial logistics market by 2030?

The market is expected to reach USD 9.04 billion by 2030, reflecting a 9.27% CAGR over 2025-2030.

Why is cold-chain logistics growing faster than ambient services?

Biologics, cell therapies, and gene therapies require stringent temperature control, driving cold-chain revenue, which held 65.57% share in 2024 and is expanding at an 11.85% CAGR.

Which region will witness the strongest growth in clinical trial logistics?

Asia-Pacific leads with an 11.05% CAGR as China surpasses the United States in annual trial starts and regional regulators streamline approvals.

How are decentralized trials altering logistics requirements?

Direct-to-patient delivery networks demand last-mile coordination, home-delivery liability coverage, and real-time monitoring platforms that traditional depot models do not provide.

What role do CROs and CMOs play in market expansion?

CROs/CMOs are the fastest-growing end-user segment at 11.32% CAGR because sponsors outsource specialized logistics, regulatory compliance, and technology capabilities.

What technologies are providers adopting to stay competitive?

IoT sensors, blockchain traceability, AI-based demand forecasting, and integrated RTSM-TMS platforms enhance visibility, compliance, and operational efficiency across global supply chains.

Clinical Trial Logistics Market Report Snapshots